FGF23 and chronic kidney disease: Given the link of increased serum FGF23 to various tissue injuries, as well as evidence that the sources of FGF23 and control of its production in AKI and CKD differ from those in the physiologic conditions, mediators of inflammation contributing to elevated FGF23 have recently been proposed as potential drug targets, in addition to repurposing existing strategies to target FGF23 (Musgrove and Wolf, 2020).